Oct. 22 at 10:57 PM
$IRWD
Takeda paid
$1.2 B upfront cash plus
$10 B biobucks for royalties and milestones to Innovent bio in anticipated revenues losses in 2030 after patent expires.
They also own SBS drug Gattex fetched in
$966 M revenues in 2024 and similar ranges for 2025.
Gattex patent expires on 5/16/26
By the same logic Why not pay
$1 B total cash to IRWD for both Linzess revenue 50% of
$850 M and a quick and shorter confirmatory Ph3 Arpa that was paid for
$1 B 2 yrs ago to fend off generic Gatter drug ?
Takeda has the existing sales and market management team that can easily to jump start Apra upon FDA approval.
I strongly believe there’re multiple suiters for Apra and of course that Linzess mature and stable REVENUE is super enticing to any BP or even to a small player in same field like ARDX.
https://www.fiercebiotech.com/biotech/takeda-pays-innovent-12b-upfront-rights-2-cancer-candidates
